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A B S T R A C T
Purpose. – To develop a questionnaire based on patients’ verbal descriptors, to measure the painful
symptoms of endometriosis.
Methods. – We performed a two-round modiﬁed DELPHI procedure mixing endometriosis patients and
physicians to select a set of statements to describe the painful symptoms of endometriosis. Each panelist
rated each statement based on diagnosis validity and clarity. The clinicians were experts in
endometriosis management selected from various geographic regions in France. Patients were women
with surgically conﬁrmed endometriosis who volunteered from a patient association and from the
recruitment of the participating physicians. The ﬁrst round questions were derived from words and
phrases in narratives of pain by endometriosis patients.
Results. – Overall, 76 experts were invited, and of these 56 (74%), comprising 33 patients and
23 gynecologists, responded to the ﬁrst round questionnaire, and 40 (71.4%) to the second round. Among
the 48 statements assessed in the ﬁrst-round questionnaire, 11 were selected after completion of the two
round DELPHI procedure. After discussion and rewording of some items, a total of 21 questions were
selected during a ﬁnal face-to-face meeting. The content of the ﬁnal questionnaire is organized according
to four dimensions: (i) spontaneous pelvic pain and dysmenorrhea, (ii) dyspareunia, (iii) painful bowel
symptoms, (iv) and other symptoms. We also provide an English (UK) version produced using several
steps of translation and back-translation.
Conclusions. – The questionnaire has content validity to measure the subjective experiences of patients
with painful endometriosis and can provide a solid basis on which to develop an efﬁcient patient-
centered outcome to measure the painful symptoms in therapeutic or in diagnostic studies of
endometriosis.
C 2017 Elsevier Masson SAS. All rights reserved.
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Endometriosis is a painful chronic disease affecting about 10%
of women in Organisation for economic co-operation and
development (OCDE) countries [1]. Endometriosis is responsible
A. Fauconnier et al. / J Gynecol Obstet Hum Reprod 47 (2018) 69–7970for various pelvic pain symptoms [2] that can have a great impact
on all aspects of the life of endometriosis patients [3].
Measuring pain symptoms and Health-related quality of life
(HrQol) in endometriosis patients was useful to assess treatment
outcome in clinical trials including medical therapy, or surgery
[4,5]. Various methods of pain assessment are available in the
context of endometriosis, some of which have been validated
with a high level of evidence. The visual analog scale (VAS) and
the numerical rating scale (NRS) are the most frequently used
pain scales to assess each type of typical pain related to
endometriosis (dysmenorrhea, deep dyspareunia and non-
menstrual chronic pelvic pain). Although these scales are
appropriate for the measurement of the individual pain
symptoms [6], they do not take into account the heterogeneity
of the painful symptoms of endometriosis. Furthermore, each of
the pain symptoms that may relate to endometriosis involves
numerous distinct descriptors and there was considerable
variability in symptom description and interpretation by
patients and by physicians [7].
Therefore, there is a need for reliable and well-deﬁned patient-
reported outcome measures (PRO’s) that can be used to determine
the clinical beneﬁt of medical interventions and/or promote early
diagnosis of endometriosis [8]. Important efforts have been made
to develop and validate HrQol questionnaire in the context of
endometriosis, see for example SF-36 [9], or The ‘‘Endometriosis
Health Proﬁle 30’’ (EHP-30), specially developed to capture the
impact of endometriosis on speciﬁc domains of HrQol [10]. Al-
though endometriosis symptom questionnaires have already been
used in an epidemiological surveys [11] and in clinical studies [12],
to the best of our knowledge, the various existing pain
questionnaires and pain scales to assess symptoms related to
endometriosis were primarily developed on the basis of clinician
input. Currently, there are few data on the patients’ descriptions of
symptoms and at the present time, no questionnaire is available to
obtain data from patients.
In a previous study, by analyzing in-depth interviews with
endometriosis patients, we identiﬁed numerous verbal descriptors
representing the patients’ experience [7]. Here, we describe a ﬁrst-
step questionnaire development based on these verbal descriptors
to measure the chronic pain symptoms of endometriosis using a
PRO’s approach. To achieve this, consensus needs to be reached
among the various stakeholders involved in the care of women
with endometriosis as well as patient representatives. The aim was
to select a set of relevant statements based on patients’ perception
of painful symptoms to construct a short, standardized self-
administered questionnaire.
Methods
We conducted a two-round modiﬁed DELPHI survey among a
multidisciplinary expert panel comprising endometriosis patients
and physicians, whether gynecologists or not, involved in the
diagnosis and treatment of endometriosis. The Delphi method is a
practical and structured method to achieve a convergence of
opinion and a general consensus on a particular topic from a large
number of individuals. It has been used to develop medical
recommendations clinical guidelines, questionnaire or clinical
indicators such as indicators reﬂecting patient and general
practitioner perceptions of chronic illness. The participants take
part anonymously in sequential questionnaires that constitute
different rounds [13]. The panellists rate the statements, and
statements made by participants at each round of the process can
be used to formulate the next round of questions. For the purpose
of the present study, we used a modiﬁed Delphi technique in which
questionnaire rounds were followed by a physical meeting of thepanellists, to enhance the complex decision-making process and to
clarify the language used to describe each statement [14].
Pre-selection of statements
First round questionnaire statements were developed from
previous qualitative research [7]: The statements were based on
the fully-comprehensive descriptions of painful symptoms obtai-
ned by qualitative, interview-based study and analyzed using
Colaizzi’s method [15], with endometriosis patients selected to
represent different types of endometriosis (i.e. superﬁcial endo-
metriosis, ovarian endometriosis, or deeply inﬁltrating endome-
triosis [DIE]). To ensure a proper formulation of the ﬁrst round
statements, we ﬁrst designed an in-person focus group discussions
with eights subjects with endometriosis and interested in
describing the word of pain (these subjects were not further
involved in the DELPHI). The discussion was centered on the
meaning of the words and sentences used to describe endometri-
osis pain related symptoms in order to reformulate some of the
items and to clarify some of the sentences used. No physician was
present at the time of the focus group discussion. The participating
women also recommended to add two themes ‘‘fears from sexual
intercourse because of the pain’’ #26 and ‘‘difﬁculties to get
pregnant’’. In total, 48 statements were identiﬁed and were used
for the ﬁrst round questionnaire. These statements fall into ﬁve
general categories:
 severe pelvic pain and dysmenorrhea (n = 21);
 dyspareunia (n = 6);
 gastro-intestinal symptoms (n = 8);
 painful urinary tract signs (n = 6);
 other symptoms (n = 7).
Panel members
To form a representative expert panel, the aim was to gather a
heterogeneous group in order to ensure that the broadest spectrum
of opinion was obtained. The clinicians were recognized French-
speaking experts in endometriosis including gynecologist sur-
geons, specialists in reproductive medicine and specialists in pelvic
imaging. They were selected from various geographic regions
within France and Belgium, and were in practice in university
teaching hospitals, general hospitals or in private centers to ensure
that they represented a wide array of clinical approaches,
backgrounds and practices. The panelists were also selected to
represent a broad range of age and experience levels. Endometri-
osis patients were volunteers diagnosed with endometriosis by
surgery; the patients came from a French association of patients
with endometriosis (Endofrance, http://www.endofrance.org/)
and from the recruitment of the participating physicians. We
planned to include about 30 panelists by stakeholder category (i.e.
physicians and patients).
First round
The panelists who agreed to participate received the ﬁrst
questionnaire by e-mail. Non-responders were re-contacted by e-
mail and telephone. Each panelist was invited to rate the
48 statements for two aspects:
 diagnosis validity, i.e. the statement had the appropriate
characteristics to effectively diagnose endometriosis, it appea-
red to be sufﬁciently sensitive and/or speciﬁc to help detect
endometriosis patients from patients with other diseases or free
of any pathology;
Table 1
Characteristics of the panelists.





Physician-based recruitment 15 45
Association-based recruitment 18 55
Age of patient, years (range) 35 (31–37)
Mean time since diagnosis, years (range) 2 (1–4)
III-IV stage 19 58
Intestinal endometriosis 7 21
Physiciansa 23
Age of physician, years (range) 49 (44–57)
Years of practice (range) 18 (11–29)
Practice location
Teaching hospital 14 61
Non-teaching hospital 3 13
Private practice 6 26
a Twenty-two were gynecologists and one a radiologist.
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unambiguous terms for both clinicians and patients.
Diagnosis validity and clarity were each rated on a 9-point
scale, where 1 meant deﬁnitely not valid or not clear and
9 deﬁnitely valid or clear statements. The questionnaire also
invited the panelists to comment on each of the statements and to
suggest additional statements not included in the list.
The central tendency was based on the median of the ratings
and agreement among panelists expressed as a percentage. We
selected statements for which a consensus was achieved regarding
diagnosis validity and clarity: i.e. for which the median score was
in the top tertile (7–9) and at least 65% of panel ratings were in the
top tertile, for both diagnosis validity and clarity.
If consensus was achieved regarding diagnosis validity only, the
statement could be rephrased according to the panelists’
comments and proposed for rating in the second round. At the
end of the ﬁrst round, the questionnaire was modiﬁed and some
statements were added or modiﬁed to take the panelists’
comments and suggestions into account. When the experts’
comments seem relevant, deleted statements were either modiﬁed
or added in the second round without any modiﬁcation.
Second round
Each of the panelists who had participated in the ﬁrst round was
sent the second-round questionnaire by mail. These panelists were
also given feedback on the results of the ﬁrst round (median panel
rating for diagnosis validity and for clarity, frequency distribution
and their individual ratings). They were asked to re-rate each
statement based on both their own opinion and the panel
responses obtained during the ﬁrst round. To be included in the
ﬁnal set, statements had to have median diagnosis validity and
clarity ratings in the top tertile (7–9) and 75% agreement among
panelists that the rating was in the top tertile [14]. We also
compared patients’ and practitioners’ responses in term of
statements selected.
Face-to-face meeting
All panel members were invited for this consensus meeting
during which an overview of the results of the second round
ratings was provided. The meeting was chaired by three of the
authors (A.F., S.S. and R.B.). Results of the second round were
discussed to identify areas of disagreement. This meeting also
allowed clariﬁcation or rephrasing of accepted statements.
Translation into English of the ﬁnal set of questions
The translation was performed according to previously
published guidelines [16]. Three native English-speaking women,
bilingual in French, involved in the ﬁeld of gynecology translated
the French version into an English draft version. Together, the
translators consolidated their translations into a single ﬁrst English
version. Then, three French native bilingual health-care providers
experienced in gynecology, back-translated this ﬁrst version into
French (without having seen the original French version). The three
initial translators then reviewed the three back-translation against
the original English version, and provided a ﬁnal forward
translation.
Results
Seventy-six patients and obstetricians/gynecologists were
invited to be part of the DELPHI expert panel. The panel thus
consisted of 40 obstetricians/gynecologists and 36 patients.Among them, 56 (74%) responded to the ﬁrst round questionnaire.
Of these, 33 were patients and 23 were obstetricians/gynecologists
(all listed in alphabetic order in the ‘‘Acknowledgment’’ section).
Table 1 reports the main characteristics of the panelists who
responded to the ﬁrst round questionnaire.
Fig. 1 shows the workﬂow of statements that were included,
deleted or suggested in each of the two rounds and the face-to-face
meeting. The ﬁnal results with levels of agreement in the two
rounds are presented in Table 2.
The ﬁrst round was performed from 15th January 2014 to
13th October 2014. ‘‘#2: very painful menstruation’’ and ‘‘#29 pain
when passing a stool, painful bowel movements’’ had the diagnosis
validity ratings with the strongest agreement (respectively 93%
and 83.3%). ‘‘#31: diarrhea during menstruation’’ had the clarity
ratings with the strongest agreement (96%). Twenty-three percent
of statements reached the ﬁrst level of consensus (11/48). Among
these 11 statements, only 4 were not modiﬁed (‘‘#2: very painful
menstruation’’, ‘‘#24: pain in certain positions during sexual
intercourse’’, ‘‘#25: deep internal pain felt during sexual inter-
course’’ and ‘‘#49: difﬁcult to get pregnant’’). One statement ‘‘#22:
strong, sharp pain during sexual intercourse’’ was discarded
because it was merged with ‘‘#23: distracting pain that prevents or
interrupts sexual intercourse’’ (Table 2). Twenty other statements
were discarded (42%) because they didn’t reach the required level
of consensus. 16/48 (33%) statements didn’t reached consensus
level but were maintained based on the feedback from the
participants. Modiﬁcations were made to 11 of these statements
(Table 2). One new statement was added (need to strain to start
passing water, difﬁcult to empty the bladder completely, especially
during menstruation), producing 28 statements to be rated for the
second round.
The second round was conducted between November 11,
2014 and April 01, 2015. It was completed by 40 (40/56: 71%)
panelists. Of these, 20 (50%) were patients and 20 (50%) were
clinicians. At this step of the process, 28 statements were therefore
evaluated, including modiﬁed, retained or additional statements.
The panel selected 11/28 (39%) of statements as valid. Among these
‘‘# 24: pain in certain positions during sexual intercourse’’ and
‘‘#29: pain when passing a stool. Bowel movements are painful
during menstruation’’ again showed the strongest agreement for
diagnosis validity (respectively 100% and 94.4%). Seventeen
statements were discarded. Among these, 12 were the subject of
a difference in opinion between patients and physicians, i.e. the
obstetricians/gynecologists discarded all of them while patients
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Fig. 1. Flow chart of statements.
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During the physical meeting, 3 patients and 6 obstetricians/
gynecologists were present. They ﬁrst discussed the 11 statements
that were selected in the second round. All were accepted but some
modiﬁcations were made to improve face and content validity for
6 of them: for example ‘‘# 2: very painful menstruation’’ was
replaced by ‘‘pain located in the lower abdomen during
menstruation’’, ‘‘# 25: deep internal pain felt during sexual
intercourse’’ into ‘‘Intense, sharp pain deep inside during sexual
intercourse’’. For painful bowel signs, the term ‘‘during menstrua-
tion’’ was replaced by ‘‘especially (worse) during menstruation’’
(Table 2). Secondly, the 12 statements where patients and
physicians did not agree (Table 3) were discussed. Of these, 6 were
deﬁnitively discarded, mostly because they did not provide useful
information at the medical level and/or may have multiple
interpretations (i.e. ‘‘# 15: pain located in the ovaries’’, ‘‘# 14:
uterine cramps’’, or ‘‘# 34: Bloating, bloated abdomen during
menstruation’’). Conversely, four among these statements were
ﬁnally re-instated because the practitioners and the patients
agreed that these statements, although they were not discriminant
for the diagnosis of endometriosis, they reﬂected well the
perception that the patients had of their pain symptoms: ‘‘# 6:
Pain starts a few days before menstruation begins and continues
for a few days after menstruation has stopped’’; #17: the pain
spreads to your back, in the lower back area’’; ‘‘#18: the pain
spreads to the legs and hips; ‘‘# 20: pain makes standing, walking
or moving difﬁcult if not impossible’’. Two statements were
reformulated: ‘‘# 1: pain located in the lower abdomen’’ became
‘‘Pain located in the lower abdomen, outside the menstrual period’’
and ‘‘# 31: diarrhea during menstruation’’ became ‘‘Diarrhea and/or constipation especially (worse) during menstruation’’. Two
statements regarding painful urinary tract signs that were
discarded during the ﬁrst round, ‘‘# 36: the urge to urinate is
painful, pain when urinating especially during menstruation’’ and
‘‘# 42: need to strain to start passing water, difﬁcult to empty the
bladder completely, especially during menstruation’’ were merged
into ‘‘difﬁculty and/or pain when urinating especially during
menstruation’’. One statement ‘‘#43: sciatica during menstrua-
tion’’, also discarded during the ﬁrst round, was added after
discussion by the panelists present at the meeting, producing
20 statements deﬁnitively selected (Table 2).
Participants were also asked to choose the means of response
between several proposals for the self-administered questionnaire
based on the selected statements. They pointed out that some
questions (eg: # 6 or # 18) naturally call for a yes or no binary
answer, whereas other questions that would give rise to a
numerical intensity response. In order to make all the questions
homogeneous and to allow establishment of scores in the future it
was decided to choose a mixed method including a binary answer
in ‘‘Yes’’ or ‘‘No’’ followed with a rating of the symptom by 11-point
NRS, including 0. As some of the painful symptoms were found to
vary across the time, it was decided to provide two distinct NRS to
describe the pain intensity of the symptom on average, and at it
worst moment.
The ﬁnal questionnaire was then assessed in a pilot study of
18 endometriosis patients who ﬁlled out a ﬁrst draft version (n = 6)
and then a ﬁnal version (n = 12) of the questionnaire. During the
test phase of the questionnaire, the ﬁrst version underwent several
minor modiﬁcations to increase comprehension and feasibility.
The second and deﬁnitive version was well accepted. Following
remarks made by two patients, with documented bladder
Table 2
Results of round 1, 2 and panel physical meeting concerning the 48 statements scored in the ﬁrst round.
Round 1 Round 2 Physical meeting
# Item Diagnosis
validity
Clarity Status Modiﬁcation Diagnosis
validity
Clarity Status Status Modiﬁcation
Pelvic pain and dysmenorrhea
1 Lower abdominal pain 7 (54.5) 8 (77.8) Modiﬁed Pain located in the lower
abdomen
7 (57.9) 8 (83.8) Discarded but
discussed




2 Very painful menstruation 9 (92.8) 9 (94.2) Retained 9 (91.9) 9 (100) Selected Modiﬁed Pain located in the
lower abdomen during
menstruation
3 Pain that is intense,
overwhelming, violent,
unbearable
8 (64.2) 8 (72.7) Modiﬁed The pain is very intense; it
is violent, obtrusive,
unbearable
8 (76.3) 8 (78.4) Selected Selected
4 The pain increases in intensity
over time
7 (66.1) 8 (72.7) Modiﬁed As the years go by, the pain
gets worse with time
7 (86.8) 8 (89.2) Selected Selected
5 The pain lasts longer than
menstrual pain, and continues
after the bleeding has stopped
7 (55.4) 8.5 (79.6) Discarded / / /
6 Pain starts a few days before
menstruation begins
7 (50.9) 9 (90.4) Modiﬁed Pain starts a few days
before menstruation begins
and continues for a few
days after menstruation
has stopped
7 (63.2) 9 (94.4) Discarded but
discussed
Selected
7 Pain before, during and after
menstruation
7 (54.5) 9 (83.0) Discarded / / /
8 Pain depends on the time of the
monthly cycle
7 (52.7) 7 (57.4) Discarded / / /
9 Pain throughout the monthly
cycle, present all the time
6 (47.3) 8 (77.8) Discarded / / /
10 Continuous pain with peaks or
attacks of more intense pain
7 (56.4) 8 (72.2) Discarded but maintained 7 (68.4) 8 (86.1) Discarded but
discussed
Discarded Redundant with item
#11
11 Stabbing pain 9 (83.0) 7 (59.2) Modiﬁed The pain comes by ﬁts and
starts, a stabbing pain
8 (72.9) 8 (75.7) Selected Selected
12 Prickly pain, like being pricked
or having an injection
5 (27.8) 8 (69.8) Discarded / / /
13 Lower abdominal burning pain 5 (31.5) 8 (71.7) Discarded / / /
14 Uterine cramps 6.5 (50.0) 8 (66.7) Discarded but maintained 6 (40.5) 8 (70.3) Discarded but
discussed
Discarded
15 Ovarian pain 7 (57.4) 8 (61.5) Modiﬁed Pain located in the ovaries 6 (45.9) 8 (69.4) Discarded but
discussed
Discarded
16 Pain on one side, pain stronger
on one side
6 (40.7) 8 (77.3) Discarded / / /
17 Pain spreads towards the back 7 (53.8) 9 (75.5) Modiﬁed Pain spreads towards the
back, in the lumbar area
7 (56.8) 9 (86.5) Discarded but
discussed
Selected
18 Pain spreads to the legs and
hips
7 (50.9) 9 (76.9) Discarded but maintained 7 (57.1) 9 (88.9) Discarded but
discussed
Selected
19 Different types of pain at the
same time, several different
pain symptoms
7 (52.8) 7 (54.9) Discarded but maintained 6 (48.6) 7 (58.3) Discarded but
discussed
Discarded
20 Paralyzing, handicapping pain
that affects mobility, difﬁculty
walking
6 (49.1) 8.5 (73.1) Modiﬁed Pain makes standing,
walking or moving difﬁcult
if not impossible














































Table 2 (Continued )
Round 1 Round 2 Physical meeting
# Item Diagnosis
validity
Clarity Status Modiﬁcation Diagnosis
validity
Clarity Status Status Modiﬁcation
21 Pain interferes with daily life 9 (79.2) 9 (86.5) Modiﬁed Pain makes normal daily
activities difﬁcult or
impossible
8 (77.8) 9 (97.2) Selected Selected
Dyspareunia
22 Strong, sharp pain during
sexual intercourse
7.5 (67.3) 9 (80.4) Discarded / / /
23 Distracting pain that prevents
or interrupts sexual intercourse








24 Pain in certain positions during
sexual intercourse
8 (81.1) 9 (94.2) Retained 8 (100) 9 (100) Selected Selected
25 Deep internal pain felt during
sexual intercourse
8 (80.8) 9 (90.0) Retained 8 (89.2) 9 (100) Selected Modiﬁed Intense, sharp pain
deep inside during
sexual intercourse
26 Nervous about having sexual
intercourse because of the pain
8 (65.4) 9 (86.0) Modiﬁed Nervous about having
sexual intercourse because
of the pain, vaginismus
8 (54.0) 8 (77.8) Discarded but
discussed
Discarded
27 Burning feeling during or after
sexual intercourse
5 (37.8) 9 (76.5) Discarded / / /
Painful bowel signs
28 Anal pain 5 (37.0) 9 (78.4) Discarded / / /
29 Pain when passing a stool,
painful bowel movements









30 Spasms, cramp, pain in the
bowel before having a bowel
movement
8 (61.1) 9 (81.1) Modiﬁed Spasms, cramp, pain in the
bowel before having a
bowel movement during
menstruation












32 Diarrhea alternating with
constipation
6.5 (50.0) 9 (84.3) Discarded / / /
33 Constipation during
menstruation
6 (49.1) 9 (86.5) Discarded / / /
34 Bloating, bloated abdomen 7 (51.8) 9 (76.9) Modiﬁed Bloating, bloated abdomen
during menstruation
7 (59.5) 9 (88.9) Discarded but
discussed
Discarded
35 Bloody stools 7 (52.8) 9 (92.4) Discarded / / /
Painful urinary tract signs




6 (48.6) 9 (97.1) Discarded but
discussed




37 Pain with urge to urinate, pain
when holding back











































Table 2 (Continued )
Round 1 Round 2 Physical meeting
# Item Diagnosis
validity
Clarity Status Modiﬁcation Diagnosis
validity
Clarity Status Status Modiﬁcation
38 Painful pressure on the bladder 5 (36.5) 8 (65.3) Modiﬁed Pain in the bladder,
especially during
menstruation
6 (41.7) 8 (73.5) Discarded but
discussed
Discarded
39 Difﬁcult to start urination 4 (32.1) 9 (83.7) Discarded / / /
40 Feeling the need to urinate
often, only small quantities at a
time
4.5 (33.3) 9 (84.3) Discarded / / /
41 Bloody urine 5 (37.2) 9 (88.5) Discarded / / /
42 Addeda Need to strain to start








43 Sciatica during menstruation 7 (53.7) 8 (65.4) Discarded / Rehabilitated Sciatica during
menstruation
44 Pain in the right shoulder 5 (38.9) 8 (71.1) Modiﬁed Pain in the right shoulder or
below the right rib cage
during menstruation
6 (48.6) 8 (87.9) Discarded but
discussed
Selected
45 Pneumothorax – air between
the lung and chest wall causing
chest pain
3 (28.3) 7 (51.9) Discarded / / /
46 Nausea, vomiting 5 (38.5) 9 (83.0) Discarded / / /
47 Dizziness, fainting 5 (37.7) 9 (80.8) Discarded / / /
48 Becoming increasingly tired,
extreme exhaustion, slowing
down
8 (59.3) 9 (86.5) Modiﬁed Extreme fatigue, total
exhaustion which
interferes with daily life
7 (51.4) 9 (86.1) Discarded but
discussed
Discarded
49 Difﬁcult to get pregnant 9 (75.0) 9 (90.0) Retained 8 (80) 9 (88.9) Selected Modiﬁed Difﬁcult to get
pregnant, failure to
conceive after several
months or years of
trying













































Twelve items with discrepancy between opinions of the patients and physicians in round 2.





#1: pain located in the lower abdomen 7 55.3 8 83.8 Discarded Retained but modiﬁed
Patients 8 88.9 9 88.2 Retained
Physicians 5.5 25 8 80 Discarded
#6: pain starts a few days before menstruation begins
and continues for a few days after menstruation has
stopped
7 63.2 9 94.4 Discarded Selected
Patients 8.5 94.4 9 100 Retained
Physicians 6 35 9 89.5 Discarded
#10: continuous pain with peaks or attacks of more
intense pain
7 68.4 8 86.1 Discarded Discarded because redundancy
Patients 9 88.9 9 93.7 Retained
Physicians 6.5 50 8 80 Discarded
#14: uterine cramps 6 40.5 8 70.3 Discarded Discarded
Patients 8 76.5 9 82.3 Retained
Physicians 5.5 10 7 60 Discarded
#15: pain located in the ovaries 6 45.9 8 69.4 Discarded Discarded
Patients 8 82.3 9 100 Retained
Physicians 5 15 6 42.1 Discarded
#17: pain spreads towards the back, in the lumbar area 7 56.8 9 86.5 Discarded Selected
Patients 8 82.3 9 100 Retained
Physicians 6 35 8 75 Discarded
#18: pain spreads to the legs and hips 7 57.1 9 88.9 Discarded Selected
Patients 8 76.5 9 100 Retained
Physicians 6 38.9 8 78.9 Discarded
#19: different types of pain at the same time, several
different pain symptoms
6 48.6 7 58.3 Discarded Discarded
Patients 8 77.8 9 76.5 Retained
Physicians 5 21.1 6 42.1 Discarded
#20: pain makes standing, walking or moving difﬁcult if
not impossible
7 55.6 9 88.6 Discarded Selected
Patients 9 88.2 9 100 Retained
Physicians 4 26.3 8 78.9 Discarded
#31: diarrhea during menstruation 8 70.3 9 97.1 Discarded Retained but modiﬁed
Patients 8 82.3 9 93.7 Retained
Physicians 7 60 8 100 Discarded
#34: bloating, bloated abdomen during menstruation 7 59.5 9 88.9 Discarded Discarded
Patients 8 88.2 9 100 Retained
Physicians 5 35 8 80 Discarded
#48: extreme fatigue, total exhaustion which interface
with daily life
7 51.4 9 86.1 Discarded Discarded
Patients 9 88.2 9 100 Retained
Physicians 6 20 8 75 Discarded
Bold results represent results of all the panel (patients + physicians), and in italic the results splitted according the statut of the pannelist.
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introduced a new question ‘‘Pain in the bladder, when you want to
urinate, or when holding back, especially during your period’’ was
ﬁnally re-introduced based on questions # 37 and 38 (Table 2). The
French ﬁnal version is available in supplementary material. The
ﬁnal English version is given in Appendix.
Discussion
We provide a brief (21 statement) self-assessed questionnaire
to measure speciﬁcally the painful symptoms of endometriosis.
The questions were derived from words and phrases in narratives
of pain from endometriosis patients and selected by a panel of
patients and physicians to speciﬁcally represent accurate des-
criptors of endometriosis pain symptoms but are also useful from a
medical point of view. The content of the questionnaire is
displayed according to four dimensions: spontaneous pelvic pain
and dysmenorrhea, dyspareunia, painful bowel symptoms, and
other symptoms, that may reﬂect the heterogeneity of the painful
experience of endometriosis. The set of questions and their means
of response enable one or several aggregated indexes to beconstructed to characterize the pain of endometriosis for use as a
PRO.
Our model addresses the difﬁculties encountered in measuring
pain in endometriosis patients. First of all, the pain symptoms are
heterogeneous among patients, which is problematic when using
pain as an outcome. In an earlier randomized controlled trial (RCT),
comparison of the effects of medroxyprogesterone acetate to
danazol and placebo involved six distinct before and after
measurement pain scores: pelvic pain, lower back pain, defecation
pain, dysuria, dyspareunia, and diarrhea. By chance most of these
symptoms were very sensitive to the treatments effects [17]. Con-
versely, the difﬁculties were more obvious in one RCT comparing
excisional laparoscopic surgery to placebo for the treatment of
painful endometriosis [5]. Although surgery appeared to be
efﬁcient for pain, it was not possible to discriminate the effect
of surgery from that of the placebo by measuring the individual
painful symptoms separately.
Furthermore, we used a PRO approach by formulating reliable
questions using the words, phrases and pain descriptors used by
patients rather than those usually used by physicians and assessing
content validity by the DELPHI method. The DELPHI method
presents many advantages that enable it to deal successfully with
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Unlike other consensus methods, individuals can be included
anonymously and without interacting directly with each other,
which prevents the views of a minority from dominating the group
[18]. The strength of the present study lies in the fact that both
patients and practitioners were involved in the design of the
questionnaire. It appears that doctors reject certain items when the
information provided by the patients about their symptoms is not
really useful for their management (non-discriminatory sign, or
without prognostic value) and/or with ambiguous or erroneous
meanings depending on the patient (see for example ‘‘ovarian
pain’’), and favor the signs that are useful for medical management
of the disease. The DELPHI process, mixing different stakeholders,
made it possible to select items that are easy to understand and
represent the subjective experience of endometriosis, but that are
also useful from a medical point of view [19].
From the methodological point of view, the fact that some
statements (i. e. those involving differences in judgment between
patients and practitioners) initially discarded were discussed and
ﬁnally retained thus bypassing the approval criteria deﬁned in
the method section might be a deviation with the strict
methodology of DELPHI. However, the modiﬁed Delphi method
that we used allows for some ﬂexibility in the process. Indeed,
the method allows the experts to express themselves and to
comment on the proposed items. In the present cases, these
items had received favorable comments, despite the disagree-
ment between the panel of practitioners and patients. So we
decided to keep them for discussion at the physical meeting of
the experts. The ﬁnal decision on each item was based not only
on the median score of validity and clarity, and the agreement
among experts expressed as a percentage, but also on the
comments of the experts and the results of the discussions
between the experts [14]. The physical meeting, at the end of the
two rounds of questionnaires, is very useful when it is difﬁcult to
reach a consensus or when uncertainties persist, as was the case
for these items; conversely absence of a meeting may deprive
the Delphi procedure of beneﬁts related to face-to-face
exchange of information, such as clariﬁcation of reasons for
disagreements or discuss comments [20]. One of the main
limitations of this study was the difﬁculty to properly assess the
exact spectrum of the disease of the patients who were included
in the DELPHI panel, as some of them were enrolled from a
patient association. Although all these patients were diagnosed
surgically, we were not able to document the location and type
of the disease, which are characteristics well known to inﬂuence
the symptoms [12]. Bladder endometriosis is a rare location of
the disease [21], which may explain the difﬁculties to reach a
deﬁnitive conclusion about painful urinary tract symptoms. For
this reason, we took the unorthodox step of reintroducing a non-
selected item in the ﬁnal questionnaire. Nonetheless, it is
important to note that the statements used in the DELPHI
process were all taken from a previous qualitative study with a
very robust control of the spectrum of the disease [7]. Moreover,
the presence in the DELPHI panel of physicians that were very
familiar with the spectrum of the disease is likely to have limited
this risk of bias.
An obvious ﬂaw of the present questionnaire building process
lies in the fact that it does not take into account the possibility of
sensitization which is a well-known phenomenon by the physician
dedicated to pain. Indeed, none of physicians dedicated to pain
treatment have been included in the expert panel. The pain
mechanisms related to endometriosis, as in other pain conditions,
likely include some degree of interrelation between endometriosis
implants and the peripheral or central nervous systems [22]. Sen-
sitization might be an important source of variability in pain
experience is that patients with identical endometriotic lesions[7]. Nonetheless, the aim of the study was to built a questionnaire
focused on pain symptoms that directly relate to endometriotic
lesions, for example related to microbleeding and or neural
invasion, and not by sensitization, which is a nonspeciﬁc
mechanism of pain, and therefore unlikely to respond to speciﬁc
endometriosis treatment.
Validated PRO’s in endometriosis are already available includ-
ing two HrQOL instruments, the SF-36 and the EHP-30. The SF-36 is
a generic instrument but has been speciﬁcally validated for
endometriosis [9]. The EHP-30 is a patient-generated instrument,
speciﬁcally developed to measure HrQOL among endometriosis
patient. A shorter and more practical version, the EHP-5 and have
proven to be a simple, efﬁcient and valid tool for evaluating quality
of life in daily practice and in clinical studies evaluating treatment
efﬁcacy [23]. Contrarily to the evaluation of the quality of life, there
is clearly a lack of instrument to evaluate symptoms of the disease
in daily clinical practice or in research setting. Since the
early 1990s, several questionnaires have been developed to
investigate the symptoms of endometriosis in epidemiological
studies. These questionnaires mainly explore three major domains,
severe dysmenorrhea, non-menstrual pelvic pain and deep
dyspareunia [11,24–28]. These questionnaires were mainly used
for research purposes. It is important to note that none of them was
speciﬁcally developed on the basis of qualitative description of the
patients’ pain experience. This may explain the fact that a limited
relationship was found between pain symptoms and endometri-
osis in these studies [22].
In the early 2000s, our group developed a questionnaire
speciﬁcally intended to evaluate endometriosis-related pain
symptoms in clinical practice [12]. The list of symptoms came
from a comprehensive review of the literature and from
retrospective collection of data from patients’ charts. Sentences
were then constructed from interviews with patients with
conﬁrmed DIE. The questionnaire included items to evaluate
dysmenorrhea, dyspareunia and non-menstrual pain. The intensity
of each symptom was evaluated according to a 10-cm VAS. Patients
also recorded whether various (urinary or gastrointestinal)
symptoms occurred or increased during menses. Using this
questionnaire we were able to build an efﬁcient prediction model
of DIE based solely on questioning [12]. However, the development
of this earlier questionnaire was not based on a structured PRO
process, unlike the current one, which includes a solid, scientiﬁc
rationale on patient description and content validation, including
face validity [29]. Indeed, face validity is an important property in
development of PROM’s because it represents the extent to which a
test is subjectively viewed as covering the concept it purports to
measure.
Apart from ours, another questionnaire concerning painful
symptoms of endometriosis, the daily electronic Endometriosis
Pain and Bleeding Diary, underwent a proper PRO process
development. The items were developed based on clinician input,
but the content validity was assessed by the mean of several focus
groups and three iterative sets of cognitive interviews with
endometriosis patients [30]. The diary covers four aspects:
dysmenorrhea, chronic pelvic pain, dyspareunia, and pain
interference. As in our study, participants highlighted that two
distinct types of pain (intermittent and continuous) existed and
were important to measure. Again as in our study, the
participants in the qualitative part of the study agreed that a
0- to 10-NRS would be appropriate to rate the pain symptoms
[30]. The collection of symptoms is based on a digital daily diary
allowing the change of pain over time to be recorded, to avoid
recall bias and to take into account the cyclicity of the symptoms
[31]. However, this renders it a complex scale to use and its
utility remains to be demonstrated in comparison with simple
pain scales such as ours.
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the spectrum of the disease, having a single instrument to measure
the painful symptoms of endometriosis in therapeutic trials,
whether medical or surgical, would help to answer the problem of
the spectrum of the disease [31]. For this reason, the Biberoglu and
Behrman scale [32] was regularly used as a primary endpoint in
earlier RCTs [33,34]. This scale takes in combination the three main
pain symptoms, dysmenorrhea, dyspareunia and non-menstrual
pelvic pain, assessed directly by the physician, as well as two signs
from physical examination. Although this scale is generally
regarded to represent the key symptoms and impact of endome-
triosis, it nonetheless suffers from several major ﬂaws and most of
all is not a PRO [31]. We thus suggest that the questionnaire we
have developed could be used to measure the painful symptoms of
endometriosis in therapeutic trials in a comprehensive and
multidimensional way, and thus include the patient’s perspective.
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